Petefészekrák: vizsgálatok itt: Japán
49 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Where
- Fukuoka, Hidaka, Kagoshima, Kashiwa, Koto, Kurume, Matsuyama, Nagoya, Niigata, Osaka, Ōta, Sapporo, Shinjyuku, Shiwa-gun, Sunto-gun,, Tōon
- Életkor
- 18 év and over
- People
- 770 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06824467 · EU 2023-508015-23-00 - 3. fázisTaking peopleA Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Where
- Akashi, Fukuoka, Hidaka, Kagoshima, Koto, Kurume, Nagoya, Niigata, Okayama, Osaka, Ōta, Sapporo, Shinjyuku, Shiwa-gun, Sunto-gun,
- Életkor
- 18 év and over
- People
- 900 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07318558 · EU 2023-508047-40-00 - 1. fázisNot yet taking people in JapánA Study of LY4336619 in Adult Participants With Advanced Solid Tumors
- Where
- Shizuoka, Tokyo
- Életkor
- 18 év and over
- People
- 370 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07928258 · EU 2026-526553-33-00 - 3. fázisTaking peopleTesting Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Where
- Akashi, Gunma, Kagoshima, Koto-ku, Kure, Minato-ku, Tokyo, Okayama, Sapporo, Sendai, Shinjuku-ku, Shiwa-gun, Tōon
- Életkor
- 18 év and over
- People
- 880 worldwide
- Run by
- NRG Oncology
See details and how to joinNCT06580314 - 3. fázisTaking peopleTorvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
- Where
- Fukushima, Ginowan-shi, Hidaka-shi, Isehara-shi, Kashiwa-shi, Kawasaki-shi, Kobe, Kōtoku, Kurume-shi, Kyoto, Minatoku, Nagoya, Niigata, Osaka, Ota-shi, Sagamihara-shi, Sapporo, Sendai, Shinjuku-ku, Shiwa-gun, Suita, Sunto-gun, Toon-Shi, Tsu, Yokohama
- Életkor
- 18 év and over
- People
- 950 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07851025 · EU 2026-526895-22-00 - 1/2. fázisTaking peopleRinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Where
- Akashi, Fukushima, Hidaka, Koto, Nagaizumi-chō, Ōta, Sapporo, Shinjuku-ku, Yamagata
- Életkor
- 18 év and over
- People
- 952 worldwide
- Run by
- Genmab
See details and how to joinNCT05579366 - 3. fázisTaking peopleEvaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Where
- Akashi, Gunma, Hiroshima, Koto-ku, Kyoto, Matsuyama, Okayama, Saitama, Sapporo, Showa-Ku Nagoya, Tokyo, Tōon
- Életkor
- 18 év to 60 év
- People
- 3960 worldwide
- Run by
- NRG Oncology
See details and how to joinNCT05879926 - 1. fázisTaking peopleA Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- Where
- Shizuoka, Tokyo
- Életkor
- 18 év and over
- People
- 575 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00 - 1. fázisTaking peopleA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Where
- Chūōku, Kashiwa, Chiba, Kōtō City, Nagoya
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00 - 2. fázisTaking peopleA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Chuo Ku, Kashiwa, Koto-ku, Nagoya, Sakai, Sapporo
- Életkor
- 18 év and over
- People
- 111 worldwide
- Run by
- Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00 - 1. fázisTaking peopleA Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Where
- Chiba, Kyoto
- Életkor
- 18 év and over
- People
- 340 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213791 · EU 2025-521887-37-00 - 3. fázisTaking peopleA Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Where
- Akashi, Chūōku, Fukuoka, Hidaka, Kagoshima, Kashiwa, Kōtoku, Nagoya, Niigata, Okayama, Otashi, Sapporo, Sendai, Shiwa-gun Yahaba-cho, Suita, Tōon, Tsu
- Életkor
- 18 év and over
- People
- 1630 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213804 · EU 2025-522255-25-00 - 3. fázisTaking peopleStudy to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
- Where
- Chuo Ku Niigata, Tokushima, Tokyo, Yamagata
- Életkor
- 18 év and over
- People
- 688 worldwide
- Run by
- Genmab
See details and how to joinNCT07564141 · EU 2025-524202-15-00 - 3. fázisTaking peopleMo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]
- Where
- Niigata, Osaka
- Életkor
- 18 év and over
- People
- 720 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07694427 · EU 2025-523365-13-00 - 3. fázisTaking peopleA Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
- Where
- Aichi, Miyagi, Osaka, Tokyo, Tsu
- Életkor
- 18 év and over
- People
- 270 worldwide
- Run by
- Verastem, Inc.
See details and how to joinNCT06072781 · EU 2023-508204-38-00 - 3. fázisTaking peopleStudy of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Where
- Akashi, Fukushima, Hidaka, Kōtoku, Kurume, Nagoya, Nakatogari, Niigata, Okayama, Osaka, Sapporo, Tokyo, Tsu, Yahaba-cho, Yamagata
- Életkor
- 18 év and over
- People
- 582 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06819007 · EU 2024-516982-35-00 - 2/3. fázisTaking peopleA Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Where
- Akashi-shi, Chūōku, Fukuoka, Hidaka-shi, Kashiwa-shi, Kōtoku, Minatoku, Nagaizumi-chō, Nagoya, Niigata, Okayama, Osaka, Sapporo, Shiwa-gun
- Életkor
- 18 év and over
- People
- 860 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06161025 · EU 2023-507914-28-00 - 2. fázisTaking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Hidaka, Kagoshima, Kanagawa, Kashiwa-shi, Matsuyama, Nagaizumi-chō, Nagoya, Osakasayama-Shi, Saitama, Tokyo, Yokohama
- Életkor
- 18 év and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - 1/2. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Chuo Ku, Kashiwa, Koto-ku, Matsuyama, Nagaizumi-chō, Nagoya, Ōsaka-sayama, Saitama
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - 1. fázisTaking peopleAnti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- Where
- Tokyo
- Életkor
- 18 év and over
- People
- 138 worldwide
- Run by
- EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07360314 · EU 2025-523232-39-00 - 3. fázisTaking peopleTorvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
- Where
- Chiba, Fukuoka, Fukushima, Gifu, Hidaka-shi, Ichihara, Kagoshima, Kobe, Kōtoku, Kurume-shi, Kyoto, Minatoku, Natori-shi, Sagamihara-shi, Shinjuku-ku, Suita-shi, Toyoake-shi, Yokohama
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07816666 · EU 2026-526776-23-00 - 1/2. fázisTaking peopleSMP-3124LP in Adults With Advanced Solid Tumors
- Where
- Kashiwa-shi, Kyoto
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- Sumitomo Pharma America, Inc.
See details and how to joinNCT06526819 - 3. fázisTaking peopleStudy to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Where
- Akashi-shi, Hidaka-shi, Kōtoku, Kurume, Matsuyama, Minatoku, Nagoya, Okayama, Osaka, Sapporo, Sendai, Shiwa-gun, Shizuoka, Tokyo
- Életkor
- 18 év and over
- People
- 466 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07214779 · EU 2025-522748-42-00 - 3. fázisTaking peopleA Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
- Where
- Fukuoka, Hokkaido, Hyōgo, Kanagawa, Mie, Okinawa, Osaka, Saitama, Tottori
- Életkor
- 18 év and over
- People
- 450 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07286266 · EU 2025-523361-25-00 - 1. fázisTaking peopleStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Where
- Chuo-Ku, Kashiwa-shi, Koto-ku, Kyoto, Nagoya, Sunto-gun
- Életkor
- 18 év and over
- People
- 325 worldwide
- Run by
- AbbVie
See details and how to joinNCT06084481 · EU 2023-506227-29-00